3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
4
Cyclophosphamide
4
Radiotherapy
3
Cisplatin
3
fludarabine
2
Doxorubicin
2
Carboplatin
2
zimberelimab
1
olaparib
1
lenvatinib
1
envafolimab
1
avelumab
1
Thymectomy
1
Taxes
1
Sunitinib
1
Robotic Surgical Procedures
1
Ramucirumab
1
Radiotherapy, Adjuvant
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Drug Therapy
1
Chemoradiotherapy
1
Cetuximab
1
AP 1903 reagent
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
AP 1903 reagent
×
1 year
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled